Dermata Therapeutics, Inc.
DRMA
$1.18
-$0.04-3.28%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.39M | 4.47M | 4.49M | 3.97M | 3.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.53M | 10.12M | 8.97M | 8.04M | 7.53M |
| Operating Income | -11.53M | -10.12M | -8.97M | -8.04M | -7.53M |
| Income Before Tax | -11.27M | -9.82M | -8.69M | -7.79M | -7.33M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.27 | -9.82 | -8.69 | -7.79 | -7.33 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.27M | -9.82M | -8.69M | -7.79M | -7.33M |
| EBIT | -11.53M | -10.12M | -8.97M | -8.04M | -7.53M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -19.96 | -26.01 | -31.26 | -58.29 | -84.09 |
| Normalized Basic EPS | -12.47 | -16.25 | -19.54 | -36.43 | -52.56 |
| EPS Diluted | -19.96 | -26.01 | -31.26 | -58.29 | -84.09 |
| Normalized Diluted EPS | -12.47 | -16.25 | -19.54 | -36.43 | -52.56 |
| Average Basic Shares Outstanding | 3.00M | 1.65M | 1.16M | 778.10K | 509.90K |
| Average Diluted Shares Outstanding | 3.00M | 1.65M | 1.16M | 778.10K | 509.90K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
